Drug intelligence / Profile preview

PHYX-003

Development stage: Preclinical
Lead developer: Protagenic Therapeutics
Administration: Subcutaneous

Overview

PHYX-003 is a preclinical drug candidate that was part of the pipeline of Phytanix Bio, a company acquired by Protagenic Therapeutics. It is one of five drug candidates that the former owners of Phytanix Bio (Alterola Biotech and EMC2 Capital) retain an irrevocable option to repurchase. The broader pipeline from which PHYX-003 originates includes assets aimed at therapeutic areas such as neurology, psychiatry, obesity, urology, and inflammation.

Beyond the preview

Go deeper on PHYX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHYX-003.

Explore the full profile